Build status - In Progress

Phase 3b Open-Label Multicenter Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies 221AD103 221AD301 221AD302 and 221AD205

Recruiting
99 years or below
All
1 Location

Brief description of study

This open-label, single arm clinical study is being conducted to assess the long-term safety and efficacy of aducanumab in participants with Alzheimer's disease who were actively participating in Aducanumab clinical studies 103, 205, 301, or 302 (aducanumab feeder studies) as of March 21st 2019. Participants who participated in 221AD302 will be eligible to screen at Penn. This study has a 24-month treatment period followed by a safety follow-up visit 18-weeks after the final dose.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 08 Feb 2023. Study ID: 843135

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center